CABASER(R) (Cabergoline) Product Information Update
Sep 30th 2008Drug InformationParkinson's Disease
Pfizer Australia is due to release new safety updates to the Cabaser® (cabergoline) Product Information which will come into effect on November 1, 2008. Ongoing review of clinical studies suggests that fibrosis and valvulopathy are associated with ergot-derived dopamine agonists, including Cabaser (cabergoline) and could be linked to cumulative doses of the medicine.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
